128 related articles for article (PubMed ID: 36936137)
1. Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M; Biller BMK; Clemmons D; Jørgensen JOL; Nishioka H; Takahashi Y
Front Endocrinol (Lausanne); 2023; 14():1158214. PubMed ID: 36936137
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M; Biller BMK; Clemmons D; Jørgensen JOL; Nishioka H; Takahashi Y
Front Endocrinol (Lausanne); 2022; 13():1040046. PubMed ID: 36619571
[TBL] [Abstract][Full Text] [Related]
3. Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ; Hollensen C; Biller BMK; Johannsson G; Takahashi Y; Rasmussen MH
Eur J Endocrinol; 2022 May; 187(1):27-38. PubMed ID: 35521713
[TBL] [Abstract][Full Text] [Related]
4. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
7. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
[TBL] [Abstract][Full Text] [Related]
8. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
Takahashi Y; Biller BMK; Fukuoka H; Ho KKY; Rasmussen MH; Nedjatian N; Sværke C; Yuen KCJ; Johannsson G
Pituitary; 2023 Feb; 26(1):57-72. PubMed ID: 36380045
[TBL] [Abstract][Full Text] [Related]
9. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
10. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
11. Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Juul Kildemoes R; Højby Rasmussen M; Agersø H; Overgaard RV
J Clin Endocrinol Metab; 2021 Jan; 106(2):567-576. PubMed ID: 33313798
[TBL] [Abstract][Full Text] [Related]
12. Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency.
Paton DM
Drugs Today (Barc); 2022 Oct; 58(10):509-517. PubMed ID: 36305544
[TBL] [Abstract][Full Text] [Related]
13. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues.
Yuen KCJ; Miller BS; Boguszewski CL; Hoffman AR
Front Endocrinol (Lausanne); 2021; 12():705241. PubMed ID: 34262531
[TBL] [Abstract][Full Text] [Related]
16. Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats.
Helleberg H; Lindecrona RH; Thygesen P; Bjelke M
Eur J Pharm Sci; 2022 Jan; 168():106032. PubMed ID: 34610450
[TBL] [Abstract][Full Text] [Related]
17. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
18. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study.
Juul A; Backeljauw P; Højby M; Kawai M; Kildemoes RJ; Linglart A; Zuckerman-Levin N; Horikawa R
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651161
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects.
Helleberg H; Bjelke M; Damholt BB; Pedersen PJ; Rasmussen MH
Eur J Pharm Sci; 2021 Dec; 167():106030. PubMed ID: 34601071
[TBL] [Abstract][Full Text] [Related]
20. Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative.
Petersen M; Gandhi PS; Buchardt J; Alanentalo T; Fels JJ; Johansen NL; Helding-Kvist P; Vad K; Thygesen P
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
